NCT06575205

Brief Summary

The goal of this study is to assess the efficacy of a brief 3 to 5-minute educational video on influencing intent to change behavior regarding potentially harmful over-the-counter (OTC) NSAID use in adults with chronic kidney disease (CKD), heart failure (HF), and/or hypertension (HTN). Informed by the COM-B model of behavior change, the video reviews identifying OTC NSAIDs, potential risks of NSAIDs, and general alternatives to potentially harmful NSAIDs. Participants with CKD, HF, and/or HTN identified as regular OTC NSAID users will be randomized to the VIDEO or CONTROL group. They will complete surveys immediately and 4 weeks after viewing the VIDEO or CONTROL to assess actual NSAIDs use, intent to change behavior related to NSAIDs use, capability/opportunity/motivation to change behavior, pain, and barriers to decreasing OTC NSAIDs. Findings will inform future population health initiatives to reduce potentially harmful OTC NSAIDs use.

Trial Health

55
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
1,452

participants targeted

Target at P75+ for not_applicable

Timeline
Completed

Started Aug 2023

Geographic Reach
1 country

1 active site

Status
active not recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

August 2, 2023

Completed
12 days until next milestone

First Submitted

Initial submission to the registry

August 14, 2023

Completed
6 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 28, 2024

Completed
7 months until next milestone

First Posted

Study publicly available on registry

August 28, 2024

Completed
7 months until next milestone

Study Completion

Last participant's last visit for all outcomes

March 15, 2025

Completed
Last Updated

September 3, 2024

Status Verified

August 1, 2024

Enrollment Period

6 months

First QC Date

August 14, 2023

Last Update Submit

August 29, 2024

Conditions

Keywords

Chronic Kidney DiseasesHeart FailureHypertensionOver the Counter NSAIDS

Outcome Measures

Primary Outcomes (2)

  • Contemplation Ladder score

    Intent to change behavior related to OTC NSAID use, scored from 0 (no intent to decrease OTC NSAID use) to 10 (already committed to decreasing OTC NSAID use). A higher score is the better outcome (greater intent to decrease high-risk OTC NSAIDs).

    baseline prior to viewing VIDEO or CONTROL and within 10 minutes after viewing VIDEO or CONTROL and 4 weeks later

  • Self-reported OTC NSAID use

    NSAID use over the past 30 days, reported as number of days during the past 30 that OTC NSAIDs were used. The range of responses is 0 to 30.

    baseline prior to viewing VIDEO or CONTROL and 4 weeks later

Secondary Outcomes (5)

  • Barriers to decreasing OTC NSAIDs use

    baseline prior to viewing VIDEO or CONTROL and 4 weeks later

  • Capability to decrease OTC NSAIDs use score

    baseline prior to viewing VIDEO or CONTROL and 4 weeks later

  • Motivation to decrease OTC NSAIDs use score

    baseline prior to viewing VIDEO or CONTROL and 4 weeks later

  • Rating of pain score

    baseline prior to viewing VIDEO or CONTROL and 4 weeks later

  • Opportunity to decrease OTC NSAIDs use score

    baseline prior to viewing VIDEO or CONTROL and 4 weeks later

Study Arms (2)

Video

EXPERIMENTAL

An original brief 3 to 5 minute educational video, covering themes such as: defining OTC NSAIDs and their uses, potential harms of NSAIDs, and broad general alternatives. Will involve suggestion to speak to their healthcare provider.

Behavioral: Educational video

Control

NO INTERVENTION

A static image of a standardized FDA warning label for OTC NSAIDs covering themes such as: uses of OTC NSAIDs, potential harms of NSAIDs, and suggestion to speak to their healthcare provider.

Interventions

Participants will view a brief 3-to-5-minute educational video (VIDEO), covering information that is already printed on FDA labels for OTC NSAIDs, on their own device covering themes such as: defining OTC NSAIDs, potential harms of NSAIDs, and alternatives.

Video

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Carilion Clinic patients
  • Age \> = 18 years
  • Diagnosis of CKD, HTN, and/or HF
  • E-mail address or phone number on file.
  • Able to speak and read English
  • Able to respond to an online survey and view a video

You may not qualify if:

  • Not Carilion Clinic patients
  • Age \< 18
  • No diagnosis of CKD, HTN, or HF
  • No e-mail address or phone number on file
  • Cannot speak or read English
  • Not able to respond to an online survey or view a video

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Carilion Clinic Riverside 1

Roanoke, Virginia, 24016, United States

Location

Related Publications (29)

  • Antman EM, Bennett JS, Daugherty A, Furberg C, Roberts H, Taubert KA; American Heart Association. Use of nonsteroidal antiinflammatory drugs: an update for clinicians: a scientific statement from the American Heart Association. Circulation. 2007 Mar 27;115(12):1634-42. doi: 10.1161/CIRCULATIONAHA.106.181424. Epub 2007 Feb 26. No abstract available.

    PMID: 17325246BACKGROUND
  • Arfe A, Scotti L, Varas-Lorenzo C, Nicotra F, Zambon A, Kollhorst B, Schink T, Garbe E, Herings R, Straatman H, Schade R, Villa M, Lucchi S, Valkhoff V, Romio S, Thiessard F, Schuemie M, Pariente A, Sturkenboom M, Corrao G; Safety of Non-steroidal Anti-inflammatory Drugs (SOS) Project Consortium. Non-steroidal anti-inflammatory drugs and risk of heart failure in four European countries: nested case-control study. BMJ. 2016 Sep 28;354:i4857. doi: 10.1136/bmj.i4857.

    PMID: 27682515BACKGROUND
  • Coxib and traditional NSAID Trialists' (CNT) Collaboration; Bhala N, Emberson J, Merhi A, Abramson S, Arber N, Baron JA, Bombardier C, Cannon C, Farkouh ME, FitzGerald GA, Goss P, Halls H, Hawk E, Hawkey C, Hennekens C, Hochberg M, Holland LE, Kearney PM, Laine L, Lanas A, Lance P, Laupacis A, Oates J, Patrono C, Schnitzer TJ, Solomon S, Tugwell P, Wilson K, Wittes J, Baigent C. Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. Lancet. 2013 Aug 31;382(9894):769-79. doi: 10.1016/S0140-6736(13)60900-9. Epub 2013 May 30.

    PMID: 23726390BACKGROUND
  • Choosing Wisely American Society of Nephrology NSAIDs Recommendation. https://www.choosingwisely.org/clinician-lists/american-society-nephrology-nsaids-in-individuals-with-hypertension-heart-failure-or-chronic-kidney-disease/, accessed March 2022

    BACKGROUND
  • Davis JS, Lee HY, Kim J, Advani SM, Peng HL, Banfield E, Hawk ET, Chang S, Frazier-Wood AC. Use of non-steroidal anti-inflammatory drugs in US adults: changes over time and by demographic. Open Heart. 2017 Apr 28;4(1):e000550. doi: 10.1136/openhrt-2016-000550. eCollection 2017.

    PMID: 28674622BACKGROUND
  • Davison SN, Koncicki H, Brennan F. Pain in chronic kidney disease: a scoping review. Semin Dial. 2014 Mar;27(2):188-204. doi: 10.1111/sdi.12196. Epub 2014 Feb 12.

    PMID: 24517512BACKGROUND
  • Gates, B. J., Setter, S. M., Corbett, C. F., & Baker, D. E. (2005). A Comparison of Educational Methods to Improve NSAID Knowledge and Use of a Medication List in an Elderly Population. Home Health Care Management & Practice, 17(5), 403-410.

    BACKGROUND
  • Green GA. Understanding NSAIDs: from aspirin to COX-2. Clin Cornerstone. 2001;3(5):50-60. doi: 10.1016/s1098-3597(01)90069-9.

    PMID: 11464731BACKGROUND
  • Hales CM, Martin CB, Gu Q. Prevalence of Prescription Pain Medication Use Among Adults: United States, 2015-2018. NCHS Data Brief. 2020 Jun;(369):1-8.

    PMID: 32600518BACKGROUND
  • Harirforoosh S, Asghar W, Jamali F. Adverse effects of nonsteroidal antiinflammatory drugs: an update of gastrointestinal, cardiovascular and renal complications. J Pharm Pharm Sci. 2013;16(5):821-47. doi: 10.18433/j3vw2f.

    PMID: 24393558BACKGROUND
  • Koffeman AR, Valkhoff VE, Celik S, W't Jong G, Sturkenboom MC, Bindels PJ, van der Lei J, Luijsterburg PA, Bierma-Zeinstra SM. High-risk use of over-the-counter non-steroidal anti-inflammatory drugs: a population-based cross-sectional study. Br J Gen Pract. 2014 Apr;64(621):e191-8. doi: 10.3399/bjgp14X677815.

    PMID: 24686883BACKGROUND
  • Labelle M, Beaulieu M, Paquette D, Fournier C, Bessette L, Choquette D, Rahme E, Thivierge RL. An integrated approach to improving appropriate use of anti-inflammatory medication in the treatment of osteoarthritis in Quebec (Canada): the CURATA model. Med Teach. 2004 Aug;26(5):463-70. doi: 10.1080/0142159042000218669.

    PMID: 15369888BACKGROUND
  • Lefebvre C, Hindie J, Zappitelli M, Platt RW, Filion KB. Non-steroidal anti-inflammatory drugs in chronic kidney disease: a systematic review of prescription practices and use in primary care. Clin Kidney J. 2019 May 20;13(1):63-71. doi: 10.1093/ckj/sfz054. eCollection 2020 Feb.

    PMID: 32082554BACKGROUND
  • Martin P, Tamblyn R, Benedetti A, Ahmed S, Tannenbaum C. Effect of a Pharmacist-Led Educational Intervention on Inappropriate Medication Prescriptions in Older Adults: The D-PRESCRIBE Randomized Clinical Trial. JAMA. 2018 Nov 13;320(18):1889-1898. doi: 10.1001/jama.2018.16131.

    PMID: 30422193BACKGROUND
  • McDonald DD, Amendola MG, Interlandi E, Wall K, Lewchik B, Polouse L, Pace N, Inthavong S, Li L. Effect of reading additional safety information on planned use of over-the-counter analgesics. Public Health Nurs. 2007 May-Jun;24(3):230-8. doi: 10.1111/j.1525-1446.2007.00629.x.

    PMID: 17456124BACKGROUND
  • Morrison C, Beauchamp T, MacDonald H, Beattie M. Implementing a non-steroidal anti-inflammatory drugs communication bundle in remote and rural pharmacies and dispensing practices. BMJ Open Qual. 2018 Jul 21;7(3):e000303. doi: 10.1136/bmjoq-2017-000303. eCollection 2018.

    PMID: 30057956BACKGROUND
  • Mullan J, Weston KM, Bonney A, Burns P, Mullan J, Rudd R. Consumer knowledge about over-the-counter NSAIDs: they don't know what they don't know. Aust N Z J Public Health. 2017 Apr;41(2):210-214. doi: 10.1111/1753-6405.12589. Epub 2016 Oct 24.

    PMID: 27774735BACKGROUND
  • National Kidney Foundation. Pain Medicine and Your Kidneys. https://www.kidney.org/atoz/content/painmeds_analgesics. Accessed March 2022

    BACKGROUND
  • Neafsey PJ, M'lan CE, Ge M, Walsh SJ, Lin CA, Anderson E. Reducing Adverse Self-Medication Behaviors in Older Adults with Hypertension: Results of an e-health Clinical Efficacy Trial. Ageing Int. 2011 Jun;36(2):159-191. doi: 10.1007/s12126-010-9085-9. Epub 2010 Dec 8.

    PMID: 21654869BACKGROUND
  • Pandolfe F, Crotty BH, Safran C. Medication Harmony: A Framework to Save Time, Improve Accuracy and Increase Patient Activation. AMIA Annu Symp Proc. 2017 Feb 10;2016:1959-1966. eCollection 2016.

    PMID: 28269955BACKGROUND
  • Vane JR, Botting RM. Anti-inflammatory drugs and their mechanism of action. Inflamm Res. 1998 Oct;47 Suppl 2:S78-87. doi: 10.1007/s000110050284.

    PMID: 9831328BACKGROUND
  • Ungprasert P, Cheungpasitporn W, Crowson CS, Matteson EL. Individual non-steroidal anti-inflammatory drugs and risk of acute kidney injury: A systematic review and meta-analysis of observational studies. Eur J Intern Med. 2015 May;26(4):285-91. doi: 10.1016/j.ejim.2015.03.008. Epub 2015 Apr 8.

    PMID: 25862494BACKGROUND
  • U.S. Food and Drug Administration. Acetaminophen overdose and liver injury- background and options for reducing injury. (2011) http://www.fda.gov/downloads/ AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/DrugSafetyandRisk ManagementAdvisoryCommittee/UCM164897.pdf (accessed April 27, 2022).

    BACKGROUND
  • Wehling M. Non-steroidal anti-inflammatory drug use in chronic pain conditions with special emphasis on the elderly and patients with relevant comorbidities: management and mitigation of risks and adverse effects. Eur J Clin Pharmacol. 2014 Oct;70(10):1159-72. doi: 10.1007/s00228-014-1734-6. Epub 2014 Aug 28.

    PMID: 25163793BACKGROUND
  • Whelton A. Nephrotoxicity of nonsteroidal anti-inflammatory drugs: physiologic foundations and clinical implications. Am J Med. 1999 May 31;106(5B):13S-24S. doi: 10.1016/s0002-9343(99)00113-8.

    PMID: 10390124BACKGROUND
  • Wilcox CM, Cryer B, Triadafilopoulos G. Patterns of use and public perception of over-the-counter pain relievers: focus on nonsteroidal antiinflammatory drugs. J Rheumatol. 2005 Nov;32(11):2218-24.

    PMID: 16265706BACKGROUND
  • Wongrakpanich S, Wongrakpanich A, Melhado K, Rangaswami J. A Comprehensive Review of Non-Steroidal Anti-Inflammatory Drug Use in The Elderly. Aging Dis. 2018 Feb 1;9(1):143-150. doi: 10.14336/AD.2017.0306. eCollection 2018 Feb.

    PMID: 29392089BACKGROUND
  • Zhan M, Doerfler RM, Xie D, Chen J, Chen HY, Diamantidis CJ, Rahman M, Ricardo AC, Sondheimer J, Strauss L, Wagner LA, Weir MR, Fink JC; CRIC Study Investigators. Association of Opioids and Nonsteroidal Anti-inflammatory Drugs With Outcomes in CKD: Findings From the CRIC (Chronic Renal Insufficiency Cohort) Study. Am J Kidney Dis. 2020 Aug;76(2):184-193. doi: 10.1053/j.ajkd.2019.12.010. Epub 2020 Apr 18.

    PMID: 32317121BACKGROUND
  • Zhou Y, Boudreau DM, Freedman AN. Trends in the use of aspirin and nonsteroidal anti-inflammatory drugs in the general U.S. population. Pharmacoepidemiol Drug Saf. 2014 Jan;23(1):43-50. doi: 10.1002/pds.3463. Epub 2013 May 30.

    PMID: 23723142BACKGROUND

MeSH Terms

Conditions

Renal Insufficiency, ChronicHeart FailureHypertension

Condition Hierarchy (Ancestors)

Renal InsufficiencyKidney DiseasesUrologic DiseasesFemale Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesMale Urogenital DiseasesChronic DiseaseDisease AttributesPathologic ProcessesPathological Conditions, Signs and SymptomsHeart DiseasesCardiovascular DiseasesVascular Diseases

Study Officials

  • Michelle Rockwell, PhD, RD

    Carilion Clinic

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
INVESTIGATOR
Purpose
HEALTH SERVICES RESEARCH
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Assistant Professor, Principal Investigator

Study Record Dates

First Submitted

August 14, 2023

First Posted

August 28, 2024

Study Start

August 2, 2023

Primary Completion

January 28, 2024

Study Completion

March 15, 2025

Last Updated

September 3, 2024

Record last verified: 2024-08

Locations